EGFR and hepatocellular carcinoma: In addition, anti-EGFRvIII MAb, anti-GEP MAb and VH domain antibody derived from anti-GPC3 MAb inhibit EGFR signaling, GEP signaling and Hippo signaling, respectively [40,43,44], which are strongly activated in HCC.